Mark Riner, M.D.
Dr. Riner attended the University of Oklahoma, where he earned his medical degree. He completed his internship, residency and specialty training in Gastroenterology at the University of Oklahoma.
He is Board Certified in Internal Medicine and Gastroenterology and is a Member of the American College of Gastroenterology, the American Medical Association and the Crohn’s & Colitis Foundation of America. He joined Gastroenterology Consultants in 1987.
In addition to the practice of General Gastroenterology, Dr. Riner has a special interest in acid reflux disease and Barrett’s esophagus.
Office locations
Ormond Beach West Office
Flagler Palm Coast Office
Practicing since
1987
Certifications
- American Board of Internal Medicine, 1986
- American Board of Gastroenterology, 1987
National Provider Identifier
1275521221
Licensure
Florida
Professional Clinical Positions
| 2008 - Present | Borland-Groover Clinic, P.A. | Ormond Beach, Florida |
| 1987 – 2008 | Gastroenterology Consultants, P.A. | Ormond Beach, Florida |
Administrative and Leadership Positions
| 1976 – 1978 | Instructor in Chemistry | Oral Roberts University | Tulsa, Oklahoma |
Medical Education
| 1982 | Medical Doctor | University of Oklahoma College of Medicine | Oklahoma City, Oklahoma |
Postgraduate Education
| 1982 - 1983 | Intern, Internal Medicine | University of Oklahoma | Oklahoma City, Oklahoma |
| 1983 - 1985 | Resident, Internal Medicine | University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma |
| 1985 - 1987 | Fellow, Gastroenterology | University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma |
Undergraduate Education
| 1977 | Bachelor of Science, Mathematics and Biology | Oral Roberts University | Tulsa, Oklahoma |
Professional Associations
- American Medical Association
- Florida Medical Association
- Volusia County Medical Association
- Study to investigate the safety and Efficacy of Dexloxiglumide in Female Patients with Constipation-Predominant Irritable Bowel Syndrome
- A Multi-Center Study Comparing Treatment with Esomeprazole to Lansoprazole in Patients with Moderate or Severe Erosive Esophagitis
- A Muti-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Crohn’s Disease
- A Phase Three, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis
- A Phase Three, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC 6535 Oral Tablets and 800mg BID of Asacol in the Maintenance of Remission in Subjects with Ulcerative Colitis
- A Phase Three, Multi-Center, 52-Week, Open-Label, Extension Study of the Safety and Efficacy of 25mg or 50mg of OPC-6535 Oral Tablets in the Treatment of Subjects with Ulcerative Colitis
- A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study, to Assess the Efficacy and Safety of Oral Tegaserod (6mg BID) and Placebo in Female Patients with Dyspepsia
- A One-Year, Open Label, Multi-Center, and Extension Study to Assess the Long-Term Safety of Tegaserod 6mg BID Given Orally in Female patients with Symptoms of Dyspepsia